Guillain-Barre Syndrome and Covid-19 Vaccine: A Report of Nine Patients Publisher



Karimi N^{1, 2, 3} ; Boostani R⁴ ; Fatehi F^{2, 3} ; Panahi A^{2, 3} ; Okhovat AA^{2, 3, 5} ; Ziaadini B⁶ ; Basiri K^{7, 8} ; Abdi S² ; Sinaei F² ; Rezaei M² ; Shamsaei G⁹ ; Ansari B^{7, 10} ; Nafissi S^{2, 3} Show Affiliations
Source: Basic and Clinical Neuroscience Published:2021

Abstract

Introduction: Guillain-Barre Syndrome (GBS) is an autoimmune acute inflammatory demyelinating polyneuropathy usually elicited by an upper respiratory tract infection. Several studies reported GBS associated with Coronavirus Disease 2019 (COVID-19) infection. In this study, we described nine GBS patients following the COVID-19 vaccine. Methods: In this study, nine patients were introduced from six referral centers for neuromuscular disorders in Iran between April 8 and June 20, 2021. Four patients received the Sputnik V, three patients received the Sinopharm, and two cases received the AstraZeneca vaccine. All patients were diagnosed with GBS evidenced by nerve conduction studies and/or cerebrospinal fluid analysis. Results: The median age of the patients was 54.22 years (ranged 26-87 years), and seven patients were male. The patients were treated with Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PLEX). All patients were discharged with some improvements. Conclusion: The link between the COVID-19 vaccine and GBS is not well understood. Given the prevalence of GBS over the population, this association may be coincidental; therefore, more studies are needed to investigate a causal relationship. © 2021 Iran University of Medical Sciences. All rights reserved.